Constitutive activity of G-proteins-coupled receptors: Cause of disease and common property of wild-type receptors

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 366, Issue 5, 2002, Pages 381-416

  Seifert, Roland ^a   Wenzel Seifert, Katharina ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 (3 AZABICYCLO[3.2.2]NON 3 YL) 2,3 DIHYDRO 1 METHYL 2 OXO 1H 1,4 BENZODIAZEPIN 3 YL] 3 (3 METHYLPHENYL)UREA; 2 DIPROPYLAMINO 5 METHOXY 1 METHYLTETRALIN; 2,3,5A,6 TETRAHYDRO 6 HYDROXY 3 HYDROXYMETHYL 2 METHYL 3,10A BIS(METHYLTHIO)PYRAZINO[1,2 A]INDOLE 1,4 DIONE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; AC 512; APAFANT; BAY 36 7620; BUTACLAMOL; CHLORPROMAZINE; CP 272871; DOMPERIDONE; FUB 465; G PROTEIN COUPLED RECEPTOR; GINKGOLIDE B; ICATIBANT; JMV 2004; JMV 341; JMV 431; JMV 457; JMV 509; JTE 907; MEPYRAMINE; MIDAZOLAM; MOZAVAPTAN; MUTANT PROTEIN; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; N,N DIALLYLTYROSYL 2 METHYLALANYL 2 METHYLALANYLPHENYLALANYLLEUCINE; N,N DIALLYLTYROSYLGLYCYL ALPHA (2 AMINOETHYLTHIO)HYDROCINNAMOYLLEUCINE; NALTRIBEN; NPC 17731; OLOPATADINE; PIRENZEPINE; RIMONABANT; RTI 5989 1; RTI 5989 23; RTI 5989 25; SDZ 212 769; SDZ 219 379; SERTINDOLE; THIOPERAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; CELL SURFACE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN;

BASAL CELL; CARDIOVASCULAR DISEASE; CONFORMATION; DRUG ACTIVITY; EXPERIMENTAL ANIMAL; GENETIC POLYMORPHISM; HUMAN; ISOMERISM; METHODOLOGY; NEUROPSYCHIATRY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; RNA EDITING; SIGNAL TRANSDUCTION; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENERAL ASPECTS OF DISEASE; GENETICS; METABOLISM; MUTATION; PHYSIOLOGY;

ANIMALS; DISEASE; GENE EXPRESSION REGULATION; GTP-BINDING PROTEINS; HUMANS; MUTATION; RECEPTORS, CELL SURFACE;

EID: 0036033424     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-002-0588-0     Document Type: Review

References (266)

1. 2 receptor in agonist-induced receptor dimerization. J Biol Chem 274:26079-26084
2. i activation. J Mol Cell Cardiol 29:765-775
3. 1A receptor. Inhibition by anxiolytic partial agonists. J Biol Chem 274:35469-35474
4. s-coupled receptors. FEBS Lett 419:171-174
5. 2 receptor. J Neurochem 71:799-807
6. 2 receptor. Mol Pharmacol 57:890-898
7. 1B-adrenergic receptor enhances mitogenesis and tumorigenicity. Proc Natl Acad Sci USA 88: 11354-11358
8. Ango F, Prézeau L, Muller T, Tu JC, Xiao B, Worley PF, Pin JP, Bockaert J, Fagni L (2001) Agonist-independent activation of metabotropic glutamate receptors by the intracellular protein Homer. Nature 411:962-965
9. Arvanitakis L, Geras-Raaka E, Varma A, Gershengorn MC, Cesarman E (1997) Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 385:347-350
10. 1D receptors. Neuropsychopharmacology 25:410-422
11. Bais C, Santomasso B, Coso O, Arvanitakis L, Raaka EG, Gutkind JS, Asch AS, Cesarman E, Gershengorn MC, Mesri EA, Gerhengorn MC (1998) G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator Nature 391:86-89
12. 1 receptor antagonists. Eur J Pharmacol 387:R5-R7
13. q/11-subunits in constitutive and agonist-mediated signaling. Mol Pharmacol 60:1133-1142
14. 2C receptors reveal novel inverse agonist activity of receptor ligands. J Biol Chem 269: 11687-11690
15. 1A receptor co-expressed in Spodoptera frugiperda cells. Distinguishing inverse agonists from neutral antagonists. J Biol Chem 272:32979-32987
16. Biebermann H, Schöneberg T, Schulz A, Krause G, Grüters A, Schultz G, Gudermann T (1998) A conserved tyrosine residue (Y601) in transmembrane domain 5 of the human thyrotropin receptor serves as a molecular switch to determine G-protein coupling. FASEB J 12:1461-1471
17. Birnbaumer L, Abramowitz J, Brown AM (1990) Receptor-effector coupling by G proteins. Biochim Biophys Acta 1031:163-224
18. 4c receptor. Br J Pharmacol 125:595-597
19. Bockaert J, Pin JP (1999) Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J 18:1723-1729
20. 2-adrenoceptor. Nature 374:272-276
21. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, Maffrand JP, Le Fur G, Casellas P (1997) A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272:22330-22339
22. 2: implication for intracellular signalization cross-regulation. Mol Pharmacol 55:473-480
23. Brandt SJ, Dougherty RW, Lapetina EG, Niedel JE (1985) Pertussis toxin inhibits chemotactic peptide-stimulated generation of inositol phosphates and lysosomal enzyme secretion in human leukemic (HL-60) cells. Proc Natl Acad Sci USA 82:3277-3280
24. 1D receptor-G-protein coupling: evidence for constitutive activity and multiple receptor conformations. Mol Pharmacol 57:1132-1141
25. 1-receptor antagonists in HL-60 cells, basophils and mast cells. Biochem Pharmacol 51:125-131
26. Burford NT, Wang D, Sadee W (2000) G-protein coupling of μ-opioid receptors (OP3): elevated basal signalling activity. Biochem J 348:531-537
27. α16 couples to chemotactic receptors in Xenopus oocytes. FEBS Lett 377:426-428
28. Burger M, Burger JA, Hoch RC, Oades Z, Takamori H, Schraufstatter IU (1999) Point mutation causing constitutive signaling of CXCR2 leads to transforming activity similar to Kaposi's sarcoma herpesvirus-G protein-coupled receptor. J Immunol 163:2017-2022
29. Burstein ES, Spalding TA, Brann MR (1997) Pharmacology of muscarinic receptor subtypes constitutively activated by G proteins. Mol Pharmacol 51:312-319
30. 1A receptor in Sf9 cells. Reconstitution of a coupled phenotype by co-expression of mammalian G protein subunits. J Biol Chem 270:18691-18699
31. s protein. Mol Pharmacol 56:989-996
32. Carroll FY, Stolle A, Beart PM, Voerste A, Brabet I, Mauler F, Joly C, Antonicek H, Bockaert J, Muller T, Pin JP, Prezeau L (2001) BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. Mol Pharmacol 59:965-973
33. Carter PH, Petroni BD, Gensure RC, Schipani E, Potts JT Jr, Gardella TJ (2001) Selective and nonselective inverse agonists for constitutively active type-1 parathyroid hormone receptors: evidence for altered receptor conformations. Endocrinology 142:1534-1545
34. i proteins. J Biol Chem 265: 6268-6273
35. Casarosa P, Bakker RA, Verzijl D, Navis M, Timmerman H, Leurs R, Smit MJ (2001) Constitutive signaling of the human cytomegalovirus-encoded chemokine receptor US28. J Biol Chem 276:1133-1137
36. Cassel D, Selinger Z (1976) Catecholamine-stimulated GTPase activity in turkey erythrocyte membranes. Biochim Biophys Acta 452:538-551
37. 2A-adrenergic receptor sensitivity to allosteric modulation by monovalent cations and fully effective receptor/G-protein coupling. J Biol Chem 269:29557-29564
38. 2-adrenergic receptor: reconstitution of functional interactions between pure receptor and pure stimulatory nucleotide binding protein of the adenylate cyclase system. Biochemistry 23:4519-4525
39. Cetani F, Tonacchera M, Vassart G (1996) Differential effects of NaCl concentration on the constitutive activity of the thyrotropin and the luteinizing hormone/chorionic gonadotropin receptors. FEBS Lett 378:27-31
40. Chen G, Way J, Armour S, Watson C, Queen K, Jayawickreme CK, Chen WJ, Kenakin T (2000) Use of constitutive G protein-coupled receptor activity for drug discovery. Mol Pharmacol 57:125-134
41. Chidiac P, Hebert TE, Valiquette M, Dennis M, Bouvier M (1994) Inverse agonist activity of β-adrenergic antagonists. Mol Pharmacol 45:490-499
42. 2-adrenergic receptor. Mol Pharmacol 50:662-669
43. 4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. Mol Pharmacol 55:910-920
44. Claeysen S, Sebben M, Becamel C, Eglen RM, Clark RD, Bockaert J, Dumuis A (2000) Pharmacological properties of 5-hydroxytryptamine 4 receptor antagonists on constitutively active wild-type and mutated receptors. Mol Pharmacol 58:136-144
45. Cohen DP, Thaw CN, Varma A, Gershengorn MC, Nussenzveig DR (1997) Human calcitonin receptors exhibit agonist-independent constitutive signaling activity. Endocrinology 138: 1400-1405
46. 1A receptors. Eur J Pharmacol 401:9-15
47. 1A receptors expressed in HeLa cells. Eur J Pharmacol 433:55-62
48. Costa T, Herz A (1989) Antagonists with negative intrinsic activity at δ opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 86:7321-7325
49. Costa T, Lang J, Gless C, Herz A (1990) Spontaneous association between opioid receptors and GTP-binding regulatory proteins in native membranes: specific regulation by antagonists and sodium ions. Mol Pharmacol 37:383-394
50. Cvejic S, Devi LA (1997) Dimerization of the delta opioid receptor: implication for a role in receptor internalization. J Biol Chem 272:26959-26964
51. Daeffler L, Landry Y (2000) Inverse agonism at heptahelical receptors: concept, experimental approach and therapeutic potential. Fundam Clin Pharmacol 14:73-87
52. 2 muscarinic acetylcholine receptors. Br J Pharmacol 126:1246-1252
53. De Ligt RA, Kourounakis AP, AP Ijzerman (2000) Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery. Br J Pharmacol 130:1-12
54. q in reconstituted phospholipid vesicles. Biochemistry 38:3090-3099
55. Dryja TP, Berson EL, Rao VR, Oprian DD (1993) Heterozygous missense mutation in the rhodopsin gene as a cause of congenital stationary night blindness. Nat Genet 4:280-283
56. Dupré DJ, Le Gouill CE, Rola-Pleszczynski M, Stankova J (2001) Inverse agonist activity of selected ligands of platelet-activating factor receptor. J Pharmacol Exp Ther 299:358-365
57. Duprez L, Parma J, Van Sande J, Allgeier A, Leclere J, Schvartz C, Delisle MJ, Decoulx M, Orgiazzi J, Dumont J, et al. (1994) Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nat Genet 7:396-401
58. Duprez L, Parma J, Costagliola S, Hermans J, Van Sande J, Dumont JE, Vassart G (1997) Constitutive activation of the TSH receptor by spontaneous mutations affecting the N-terminal extracellular domain. FEBS Lett 409:469-474
59. s. Mol Pharmacol 45:696-702
60. 2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs. J Pharmacol Exp Ther 286:85-90
61. Eggerickx D, Denef JF, Labbe O, Hayashi Y, Refetoff S, Vassart G, Parmentier M, Libert F (1995) Molecular cloning of an orphan G-protein-coupled receptor that constitutively activates adenylate cyclase. Biochem J 309:837-843
62. 1-receptor transgenic mice. Mol Pharmacol 60:712-717
63. 2 bradykinin receptor activity determines the action of partial agonists as agonists or inverse agonists. Effect of basal desensitization. J Biol Chem 274:29603-29606
64. 1-adenosine receptors with G-proteins. Reciprocal modulation of agonist and antagonist binding. Biochem J 275:651-656
65. Freissmuth M, Selzer E, Marullo S, Schütz W, Strosberg AD (1991b) Expression of two human β-adrenergic receptors in Escherichia coli: functional interaction with two forms of the stimulatory G protein. Proc Natl Acad Sci USA 88:8548-8552
66. 2 receptors expressed in Sf9 and COS7 cells. FEBS Lett 409:283-286
67. Ganguli SC, Park CG, Holtmann MH, Hadac EM, Kenakin TP, Miller LJ (1998) Protean effects of a natural peptide agonist of the G protein-coupled secretin receptor demonstrated by receptor mutagenesis. J Pharmacol Exp Ther 286:593-598
68. 1d-adrenoceptors. FEBS Lett 443:277-281
69. Gardella TJ, Luck MD, Jensen GS, Schipani E, Potts JT, Jüppner H (1996) Inverse agonism of amino-terminally truncated parathyroid hormone (PTH) and PTH-related peptide (PTHrP) analogs revealed with constitutively active mutant PTH/PTHrP receptors. Endocrinology 137:3936-3941
70. Gaster LM, Blaney FE, Davies S, Duckworth DM, Ham P, Jenkins S, Jennings AJ, Joiner GF, King FD, Mulholland KR, Wyman PA, Hagan JJ, Hatcher J, Jones BJ, Middlemiss DN, Price GW, Riley G, Roberts C, Routledge C, Selkirk J, Slade PD (1998) The selective 5-HT1B receptor inverse agonist 1′-methyl-5-[[2′-methyl-4′-(5-methyl-1,2,4-oxadiazol-3-yl) biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro-spiro[furo[2,3-f]indole-3, 4′-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. J Med Chem 41:1218-1235
71. Geras-Raaka E, Varma A, Ho H, Clark-Lewis I, Gershengorn MC (1998) Human interferon-gamma-inducible protein 10 (IP-10) inhibits constitutive signaling of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. J Exp Med 188:405-408
72. Gether U (2000) Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 21:90-113
73. Gether U, Kobilka BK (1998) G protein-coupled receptors. II. Mechanism of agonist activation. J Biol Chem 273:17979-17982
74. 2 adrenergic receptor. Evidence for ligand-specific conformational changes. J Biol Chem 270:28268-28275
75. Gether U, Ballesteros JA, Seifert R, Sanders-Bush E, Weinstein H, Kobilka BK (1997a) Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility. J Biol Chem 272:2587-2590
76. Gether U, Lin S, Ghanouni P, Ballesteros JA, Weinstein H, Kobilka BK (1997b) Agonists induce conformational changes in transmembrane domains III and IV of the β2 adrenoceptor. EMBO J 16:6737-6747
77. 1A receptor. Biochemistry 33:4283-4290
78. + regulation of formyl peptide receptor-mediated signal transduction in HL 60 cells. Evidence that the cation prevents activation of the G-protein by unoccupied receptors. Eur J Pharmacol 172:481-492
79. Gierschik P, Moghtader R, Straub C, Dieterich K, Jakobs KH (1991) Signal amplification in HL-60 granulocytes. Evidence that the chemotactic peptide receptor catalytically activates guanine-nucleotide-binding regulatory proteins in native plasma membranes. Eur J Biochem 197:725-732
80. Gilman AG (1987) G proteins: transducers of receptor-generated signals. Annu Rev Biochem 56:615-649
81. Götze K, Jakobs KH (1994) Unoccupiedb-adrenoceptor-induced adenylyl cyclase stimulation in turkey erythrocyte membranes. Eur J Pharmacol 268:151-158
82. Graham A, Wakamatsu K, Hunt G, Ito S, Thody AJ (1997) Agouti protein inhibits the production of eumelanin and phaeomelanin in the presence and absence of α-melanocyte stimulating hormone. Pigment Cell Res 10:298-303
83. sα in Escherichia coli. Purification and properties of two forms of the protein. J Biol Chem 264:409-418
84. 3 receptor. J Neural Transm 103:1163-1175
85. Gromoll J, Simoni M, Nordhoff V, Behre HM, De Geyter C, Nieschlag E (1996) Functional and clinical consequences of mutations in the FSH receptor. Mol Cell Endocrinol 125:177-182
86. 2C receptors revealed by heterologous expression. Naunyn Schmiedebergs Arch Pharmacol 359:21-27
87. Gudermann T, Schöneberg T, Schultz G (1997) Functional and structural complexity of signal transduction via G-protein-coupled receptors. Annu Rev Neurosci 20:399-427
88. 2-adrenoceptor on ligand affinity in transgenic mice. Mol Pharmacol 52:187-194
89. Gurwitz D, Haring R, Heldman E, Fraser CM, Manor D, Fisher A (1994) Discrete activation of transduction pathways associated with acetylcholine m1 receptor by several muscarinic ligands. Eur J Pharmacol 267:21-31
90. Hagelüken A, Grünbaum L, Klinker JF, Nürnberg B, Harhammer R, Schultz G, Leschke C, Schunack W, Seifert R (1995) Histamine receptor-dependent and/or -independent activation of guanine nucleotide-binding proteins by histamine and 2-substituted histamine derivatives in human leukemia (HL-60) and human erythroleukemia (HEL) cells. Biochem Pharmacol 49: 901-914
91. 2 dopamine receptors. Br J Pharmacol 121:731-736
92. Han M, Smith SO, Sakmar TP (1998) Constitutive activation of opsin by mutation of methionine 257 on transmembrane helix 6. Biochemistry 37:8253-8261
93. + currents in frog and rat cardiac cells. J Physiol (Lond) 461:743-765
94. 2c receptor antagonists. J Biol Chem 271:22591-22597
95. 2 receptor antagonists on a cranial nerve reflex in the rabbit: evidence for inverse agonism. Psychopharmacology (Berl) 141:162-168
96. 3 subtype different in agonist-independent constitutive activity. J Biol Chem 271:1857-1860
97. Haskell-Luevano C, Monck EK (2001) Agouti-related protein functions as an inverse agonist at a constitutively active brain melanocortin-4 receptor. Regul Pept 99:1-7
98. Hebert TE, Bouvier M (1998) Structural and functional aspects of G protein-coupled receptor oligomerization. Biochem Cell Biol 76:1-11
99. 2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J Biol Chem 271:16384-16392
100. 2C receptor RNA editing alters receptor basal activity: implications for serotonergic signal transduction. J Neurochem 73:1711-1717
101. 2C receptors. J Pharmacol Exp Ther 295:226-232
102. Hildebrandt JD (1997) Role of subunit diversity in signaling by heterotrimeric G proteins. Biochem Pharmacol 54:325-339
103. Hilf G, Jakobs KH (1992) Agonist-independent inhibition of G protein activation by muscarinic acetylcholine receptor antagonists in cardiac membranes. Eur J Pharmacol 225:245-252
104. 1 cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity. FEBS Lett 459:277-281
105. 2-adrenoceptors. Br J Pharmacol 131:124-130
106. q-protein coupling. J Neurochem 80:678-696
107. Iiri T, Farfel Z, Bourne HR (1998) G-protein diseases furnish a model for the turn-on switch. Nature 394:35-38
108. 2 receptor. J Pharmacol Exp Ther 296:420-425
109. Jacobs AA, Huber JL, Ward RA, Klein JB, McLeish KR (1995) Chemoattractant receptor-specific differences in G protein activation rates regulate effector enzyme and functional responses. J Leukoc Biol 57:679-686
110. 4 subtypes of muscarinic receptors in transfected CHO cells and of muscarinic receptors in the heart cells revealed by negative antagonists. FEBS Lett 377:275-279
111. 2A-adrenoceptors. Mol Pharmacol 53:963-968
112. 2 adrenergic receptor alters the orientation of its sixth membrane-spanning segment. J Biol Chem 272:18546-18549
113. 3 isoforms. Br J Pharmacol 121:317-323
114. i1α. Mol Pharmacol 56:684-692
115. 2-receptor with guanidine-type agonists. Mol Pharmacol 60:1210-1225
116. Kenakin T (1996) The classification of seven transmembrane receptors in recombinant expression systems. Pharmacol Rev 48:413-463
117. Kenakin T (2001) Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15:598-611
118. 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. J Biol Chem 267:1430-1433
119. Klinker JF, Schwaner I, Offermanns S, Hagelüken A, Seifert R (1994) Differential activation of dibutyryl cAMP-differentiated HL-60 human leukemia cells by chemoattractants. Biochem Pharmacol 48:1857-1864
120. Kopin AS, McBride EW, Schaffer K, Beinborn M (2000) CCK receptor polymorphisms: an illustration of emerging themes in pharmacogenomics. Trends Pharmacol Sci 21:346-353
121. + and GTP in inhibitory regulation of adenylate cyclase. J Biol Chem 257:14035-14040
122. Kosugi S, Shenker A, Mori T (1994) Constitutive activation of cyclic AMP but not phosphatidylinositol signaling caused by four mutations in the 6th transmembrane helix of the human thyrotropin receptor. FEBS Lett 356:291-294
123. Kosugi S, Van Dop C, Geffner ME, Rabl W, Carel JC, Chaussain JL, Mori T, Merendino JJ Jr, Shenker A (1995) Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty. Hum Mol Genet 4:183-188
124. 1 dopamine receptor. Mol Pharmacol 52:1137-1149
125. Krause KH, Schlegel W, Wollheim CB, Andersson T, Waldvogel FA, Lew PD (1985) Chemotactic peptide activation of human neutrophils and HL-60 cells. Pertussis toxin reveals correlation between inositol trisphosphate generation, calcium ion transients, and cellular activation. J Clin Invest 76:1348-1354
126. i2. Biochemistry 38:12490-12498
127. 2 histamine receptor to phospholipase C. Mol Endocrinol 10:1697-1707
128. Labrecque J, Fargin A, Bouvier M, Chidiac P, Dennis M (1995) Serotonergic antagonists differentially inhibit spontaneous activity and decrease ligand binding capacity of the rat 5-hydroxytryptamine type 2C receptor in Sf9 cells. Mol Pharmacol 48:150-159
129. Latronico AC, Anasti J, Arnhold IJ, Mendonca BB, Domenice S, Albano MC, Zachman K, Wajchenberg BL, Tsigos C (1995) A novel mutation of the luteinizing hormone receptor gene causing male gonadotropin-independent precocious puberty. J Clin Endocrinol Metab 80:2490-2494
130. Latronico AC, Abell AN, Arnhold IJ, Liu X, Lins TS, Brito VN, Billerbeck AE, Segaloff DL, Mendonca BB (1998) A unique constitutively activating mutation in third transmembrane helix of luteinizing hormone receptor causes sporadic male gonadotropin-independent precocious puberty. J Clin Endocrinol Metab 83:2435-2440
131. 1-adrenergic receptor. FEBS Lett 457:302-306
132. i/mitogen-activated protein kinase pathway. J Biol Chem 271:11272-11279
133. 2 dopamine receptors exist as oligomers in the cell. Mol Pharmacol 58:120-128
134. 2 receptor act as inverse agonists in rat myometrial cells. J Biol Chem 269:25970-25973
135. Leff P (1995) The two-state model of receptor activation. Trends Pharmacol Sci 16:89-97
136. Lefkowitz RJ, Cotecchia S, Samama P, Costa T (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 14:303-307
137. Leopoldt D, Harteneck C, Nürnberg B (1997) G proteins endogenously expressed in Sf 9 cells: interactions with mammalian histamine receptors. Naunyn Schmiedebergs Arch Pharmacol 356:216-224
138. iα after expression inEscherichia coli. J Biol Chem 265:8243-8251
139. Liu G, Duranteau L, Carel JC, Monroe J, Doyle DA, Shenker A (1999) Leydig-cell tumors caused by an activating mutation of the gene encoding the luteinizing hormone receptor. N Engl J Med 341:1731-1736
140. 4) expressed in bone marrow. Mol Pharmacol 59:420-426
141. sαshort: consequences for receptor-coupling and adenylyl cyclase activation. J Neurochem 78:325-338
142. 2-adrenoceptor by sustained treatment with inverse agonists but not antagonists. FEBS Lett 399:108-112
143. 2 receptor induced by
144. McAllister SD, Griffin G, Satin LS, Abood ME (1999) Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a Xenopus oocyte expression system. J Pharmacol Exp Ther 291:618-626
145. 1D-adrenoceptors by agonists and inverse agonists. Mol Pharmacol 57:659-666
146. 2-adrenoceptor-green fluorescent protein fusion proteins. Mol Pharmacol 56:1182-1191
147. 4 and N-formylmethionyl-leucylphenylalanine in HL-60 cells occurs by different mechanisms. Biochem J 260:427-434
148. 1A receptors. J Neurochem 74:347-357
149. Merkouris M, Mullaney I, Georgoussi Z, Milligan G (1997) Regulation of spontaneous activity of the δ-opioid receptor: studies of inverse agonism in intact cells. J Neurochem 69:2115-2122
150. 1 cannabinoid receptor. Biochem Pharmacol 60:1315-1323
151. Mewes T, Dutz S, Ravens U, Jakobs KH (1993) Activation of calcium currents in cardiac myocytes by empty β-adrenoceptors. Circulation 88:2916-2922
152. 2-adrenergic receptor. Science 264:582-586
153. 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci USA 91:10109-10113
154. Milligan G (2000) Insights into ligand pharmacology using receptor-G-protein fusion proteins. Trends Pharmacol Sci 21:24-28
155. 2 vasopressin receptor induces a constitutive activity which permits discrimination between antagonists with partial agonist and inverse agonist activities. FEBS Lett 441:470-475
156. 3 receptors regulates histamine neurons in brain. Nature 408:860-864
157. Morse KL, Behan J, Laz TM, West RE Jr, Greenfeder SA, Anthes JC, Umland S, Wan Y, Hipkin RW, Gonsiorek W, Shin N, Gustafson EL, Qiao X, Wang S, Hedrick JA, Greene J, Bayne M, Monsma FJ Jr (2001) Cloning and characterization of a novel human histamine receptor. J Pharmacol Exp Ther 296: 1058-1066
158. q promoted by receptor and GTPase-activating proteins. Proc Natl Acad Sci USA 96:9539-9544
159. 1 cannabinoid receptor juxtamembrane C-terminal peptide confers activation to specific G proteins in brain. Mol Pharmacol 57:162-170
160. Muller J, Gondos B, Kosugi S, Mori T, Shenker A (1998) Severe testotoxicosis phenotype associated with Asp578→Tyr mutation of the lutrophin/choriogonadotrophin receptor gene. J Med Genet 35:340-341
161. s in chicken erythrocyte membranes. Cell Signal 1:173-179
162. 2-adrenoceptor activation. Br J Pharmacol 127:1099-1104
163. s activity. FEBS Lett 386:165-168
164. Neilan CL, Akil H, Woods JH, Traynor JR (1999) Constitutive activity of the δ-opioid receptor expressed in C6 glioma cells: Identification of non-peptide δ-inverse agonists. Br J Pharmacol 128:556-562
165. 1A receptors by the inverse agonist, spiperone, but not the neutral antagonist, WAY 100,635. Br J Pharmacol 120:737-739
166. 1B receptor/G-protein stoichiometry. Mol Pharmacol 58:1042-1049
167. 3H]-WAY100,635. Br J Pharmacol 132:518-524
168. 1B receptor expression in Sf9 cells: Phosphorylation, palmitoylation, and adenylyl cyclase inhibition. Biochemistry 32:11727-11733
169. Nijenhuis WA, Oosterom J, Adan RA (2001) AgRP(83-132) acts as an inverse agonist on the human-melanocortin-4 receptor. Mol Endocrinol 15:164-171
170. 2 receptor is antagonized by R(-)-n-propylnorapomorphine, raclopride, and phenoxybenzamine. Neuropsychopharmacology 15:53-61
171. 3 receptor dimers and tetramers in brain and in transfected cells. J Biol Chem 272:29229-29237
172. 2C receptor. Ann NY Acad Sci 861:38-48
173. 2C receptor silences constitutive activity. J Biol Chem 274:9472-9478
174. Noguera MA, Ivorra MD, P DO (1996) Functional evidence of inverse agonism in vascular smooth muscle. Br J Pharmacol 119:158-164
175. Nürnberg B, Tögel W, Krause G, Storm R, Breitweg-Lehmann E, Schunack W (1999) Non-peptide G-protein activators as promising tools in cell biology and potential drug leads. Eur J Med Chem 34:5-30
176. 1 cannabinoid receptor activity. Mol Pharmacol 54:1064-1072
177. Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, Dumont J, Vassart G (1993) Somatic mutations in the thyro-tropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365:649-651
178. 2+ cascades. Mol Endocrinol 9:725-733
179. Pauwels PJ, Wurch T (1998) Review: Amino acid domains involved in constitutive activation of G-protein-coupled receptors. Mol Neurobiol 17:109-135
180. oα protein coexpression: Evidence for inverse agonism. J Pharmacol Exp Ther 292:654-663
181. 2-adrenergic receptor is constitutively desensitized and phosphorylated. Proc Natl Acad Sci USA 91:2699-2702
182. Perez DM, Hwa J, Gaivin R, Mathur M, Brown F, Graham RM (1996) Constitutive activation of a single effector pathway: Evidence for multiple activation states of a G protein-coupled receptor. Mol Pharmacol 49:112-122
183. Pieroni L, La Monica N (2001) Towards the use of baculovirus as gene therapy vector. Curr Opin Mol Ther 3:464-467
184. Pozvek G, Hilton JM, Quiza M, Houssami S, Sexton PM (1997) Structure/function relationships of calcitonin analogues as agonists, antagonists, or inverse agonists in a constitutively activated receptor cell system. Mol Pharmacol 51:658-665
185. Prezeau L, Gomeza J, Ahern S, Mary S, Galvez T, Bockaert J, Pin JP (1996) Changes in the carboxyl-terminal domain of metabotropic glutamate receptor 1 by alternative splicing generate receptors with differing agonist-independent activity. Mol Pharmacol 49:422-429
186. i proteins in the Sf9 insect cell. Characterization of the uncoupled recombinant N-formyl peptide receptor. J Biol Chem 267:19757-19760
187. 2 receptor suppress agonist-independent receptor activation. Biochemistry 35:13368-13377
188. 2-opioid receptors mediates spinal antianalgesia. J Pharmacol Exp Ther 297:582-589
189. s. J Biol Chem 263:9482-9485
190. Rao VR, Cohen GB, Oprian DD (1994) Rhodopsin mutation G90D and a molecular mechanism for congenital night blindness. Nature 367:639-642
191. 2C receptor. J Pharmacol Exp Ther 299:83-89
192. Richard F, Barroso S, Martinez J, Labbé-Jullié C, Kitabgi P (2001) Agonism, inverse agonism, and neutral antagonism at the constitutively active human neurotensin receptor 2. Mol Pharmacol 60:1392-1398
193. Robbins LS, Nadeau JH, Johnson KR, Kelly MA, Roselli-Rehfuss L, Baack E, Mountjoy KG, Cone RD (1993) Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function. Cell 72:827-834
194. 1B receptor inverse agonist, on in vivo extracellular 5-HT levels in the freely-moving guinea-pig. Naunyn Schmiedebergs Arch Pharmacol 362:177-183
195. Robinson PR, Cohen GB, Zhukovsky EA, Oprian DD (1992) Constitutively active mutants of rhodopsin. Neuron 9:719-725
196. i: Precoupling and constitutive activity. Mol Pharmacol 56:1014-1024
197. Rosenkilde MM, Schwartz TW (2000) Potency of ligands correlates with affinity measured against agonist and inverse agonists but not against neutral ligand in constitutively active chemokine receptor. Mol Pharmacol 57:602-609
198. Rosenkilde MM, Kledal TN, Brauner-Osborne H, Schwartz TW (1999) Agonists and inverse agonists for the herpesvirus 8-encoded constitutively active seven-transmembrane oncogene product, ORF-74. J Biol Chem 274:956-961
199. 2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol 126:665-672
200. Ross RA, Gibson TM, Stevenson LA, Saha B, Crocker P, Razdan RK, Pertwee RG (1999b) Structural determinants of the partial agonist-inverse agonist properties of 6′-azidohex-2′-yne-δ8-tetrahydrocannabinol at cannabinoid receptors. Br J Pharmacol 128:735-743
201. 1b-adrenergic receptor subtypes. Mol Pharmacol 56:858-866
202. 3 receptors. Br J Pharmacol 135:383-392
203. 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268:4625-4636
204. 2-adrenergic receptor. Mol Pharmacol 45:390-394
205. 2-adrenergic receptor: Pharmacological creation of a phenotype in transgenic mice. Proc Natl Acad Sci USA 94:137-141
206. Schaffer K, McBride EW, Beinborn M, Kopin AS (1998) Inter-species polymorphisms confer constitutive activity to the Mastomys cholecystokinin-B/gastrin receptor. J Biol Chem 273:28779-28784
207. Scheer A, Cotecchia S (1997) Constitutively active G protein-coupled receptors: potential mechanisms of receptor activation. J Recept Signal Transduct Res 17:57-73
208. Schipani E, Kruse K, Jüppner H (1995) A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science 268:98-100
209. Schipani E, Langman CB, Parfitt AM, Jensen GS, Kikuchi S, Kooh SW, Cole WG, Jüppner H (1996) Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia. N Engl J Med 335:708-714
210. Schipani E, Lanske B, Hunzelman J, Luz A, Kovacs CS, Lee K, Pirro A, Kronenberg HM, Jüppner H (1997) Targeted expression of constitutively active receptors for parathyroid hormone and parathyroid hormone-related peptide delays endochondral bone formation and rescues mice that lack parathyroid hormone-related peptide. Proc Natl Acad Sci USA 94:13689-13694
211. Schipani E, Langman C, Hunzelman J, Le Merrer M, Loke KY, Dillon MJ, Silve C, Jüppner H (1999) A novel parathyroid hormone (PTH)/PTH-related peptide receptor mutation in Jansen's metaphyseal chondrodysplasia. J Clin Endocrinol Metab 84: 3052-3057
212. Schreurs J, Yamamoto R, Lyons J, Munemitsu S, Conroy L, Clark R, Takeda Y, Krause JE, Innis M (1995) Functional wild-type and carboxyl-terminal-tagged rat substance P receptors expressed in baculovirus-infected insect Sf9 cells. J Neurochem 64:1622-1631
213. Schütz W, Freissmuth M (1992) Reverse intrinsic activity of antagonists on G protein-coupled receptors. Trends Pharmacol Sci 13:376-380
214. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ (1996) Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2:1254-1258
215. sα splice variants. J Pharmacol Exp Ther 298:840-847
216. + as universal stabilizer of the inactive (R) state. Receptors Channels 7:357-369
217. sα fusion protein. Eur J Biochem 255:369-382
218. sα has properties of a constitutively active receptor. J Biol Chem 273:5109-5116
219. s interactions: Evidence for multiple receptor conformations. Mol Pharmacol 56:348-358
220. α fusion proteins: An approach for the molecular analysis of receptor/G-protein coupling. Trends Pharmacol Sci 20:383-389
221. Seifert R, Wenzel-Seifert K, Gether U, Kobilka BK (2001) Functional differences between full and partial agonists: Evidence for ligand-specific receptor conformations. J Pharmacol Exp Ther 297:1218-1226
222. Selley DE, Cao CC, Liu Q, Childers SR (2000) Effects of sodium on agonist efficacy for G-protein activation in μ-opioid receptor-transfected CHO cells and rat thalamus. Br J Pharmacol 130:987-996
223. Serre V, Dolci W, Schaerer E, Scrocchi L, Drucker D, Efrat S, Thorens B (1998) Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: Implications for basal intracellular cyclic adenosine 3′,5′-monophosphate levels and beta-cell glucose competence. Endocrinology 139:4448-4454
224. 2-adrenoceptor and the parathyroid hormone receptor. Zn(II) bridges between helices III and VI block activation. J Biol Chem 274:17033-17041
225. Shenker A, Laue L, Kosugi S, Merendino JJ Jr, Minegishi T, Cutler GB Jr (1993) A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 365:652-654
226. 1 adenosine receptors stably expressed in Chinese hamster ovary cells. Mol Pharmacol 53:886-893
227. Siegrist W, Willard DH, Wilkison WO, Eberle AN (1996) Agouti protein inhibits growth of B16 melanoma cells in vitro by acting through melanocortin receptors. Biochem Biophys Res Commun 218:171-175
228. Siegrist W, Drozdz R, Cotti R, Willard DH, Wilkison WO, Eberle AN (1997) Interactions of alpha-melanotropin and agouti on B16 melanoma cells: evidence for inverse agonism of agouti. J Recept Signal Transduct Res 17:75-98
229. 2 receptors. Proc Natl Acad Sci USA 93:6802-6807
230. Takuma T (1990) Propranolol inhibits cyclic AMP accumulation and amylase secretion in parotid acinar cells stimulated by isobutylmethylxanthine and forskolin. Biochim Biophys Acta 1052: 461-466
231. 7 receptor (long form); antagonist profile of SB-258719. Br J Pharmacol 124:1300-1306
232. Thorens B, Porret A, Buhler L, Deng SP, Morel P, Widmann C. (1993) Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42: 1678-1682
233. 2-adrenergic receptor activation of G proteins: Evidence for a precoupled receptor/G protein state. Mol Pharmacol 45:524-531
234. 2A/D-adrenoceptors. J Pharmacol Exp Ther 292:664-671
235. 1B receptor subtype. J Biol Chem 269:27925-27931
236. Tonacchera M, Van Sande J, Cetani F, Swillens S, Schvartz C, Winiszewski P, Portmann L, Dumont JE, Vassart G, Parma J (1996) Functional characteristics of three new germline mutations of the thyrotropin receptor gene causing autosomal dominant toxic thyroid hyperplasia. J Clin Endocrinol Metab 81: 547-554
237. sα. J Biol Chem 275:21631-21638
238. Varma DR, Shen H, Deng XF, Peri KG, Chemtob S, Mulay S (1999) Inverse agonist activities of β-adrenoceptor antagonists in rat myocardium. Br J Pharmacol 127:895-902
239. 2A-adrenergic receptor. Mol Pharmacol 59:532-542
240. Wang W, Gershengorn MC (1999) Rat TRH receptor type 2 exhibits higher basal signaling activity than TRH receptor type 1. Endocrinology 140:4916-4919
241. 2C receptors. J Neurochem 74:1290-1300
242. 2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther 299:268-276
243. Wenzel-Seifert K, Seifert R (1993) Cyclosporin H is a potent and selective formyl peptide receptor antagonist. Comparison with N-t-butoxycarbonyl-L-phenylalanyl-L-leucyl-L-phenylalanyl-L-leucyl-L- phenylalanine and cyclosporins A, B, C, D, and E. J Immunol 150:4591-4599
244. q-proteins. Mol Pharmacol 58:954-966
245. Wenzel-Seifert K, Hurt CM, Seifert R (1998) High constitutive activity of the human formyl peptide receptor. J Biol Chem 277:24181-24189
246. 3. J Biol Chem 274:33259-33266
247. sα. J Pharmacol Exp Ther 299:1013-1020
248. sα splice variants. Biochem Pharmacol 64:9-20
249. Westphal RS, Sanders-Bush E (1994) Reciprocal binding properties of 5-hydroxytryptamine type 2C receptor agonists and inverse agonists. Mol Pharmacol 46:937-942
250. 2C receptor-mediated cell division. Mol Pharmacol 49:474-480
251. Wieland T, Jakobs K-H (1994) Measurement of receptor-stimulated guanosine 5′-O-(γ-thio)triphosphate binding by G proteins. Methods Enzymol 237:3-13
252. 3 antagonists. J Pharmacol Exp Ther 299:908-914
253. Wonerow P, Schöneberg T, Schultz G, Gudermann T, Paschke R (1998) Deletions in the third intracellular loop of the thyrotropin receptor. A new mechanism for constitutive activation. J Biol Chem 273:7900-7905
254. 1D receptors form homodimers when expressed alone and heterodimers when co-expressed. FEBS Lett 456:63-67
255. Yang BT, Chen SC, Leach MW, Manfra D, Homey B, Wiekowski M, Sullivan L, Jenh CH, Narula SK, Chensue SW, Lira SA (2000) Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. J Exp Med 191:445-454
256. Yano K, Hidaka A, Saji M, Polymeropoulos MH, Okuno A, Kohn LD, Cutler GB Jr (1994) A sporadic case of male-limited precocious puberty has the same constitutively activating point mutation in luteinizing hormone/choriogonadotropin receptor gene as familial cases. J Clin Endocrinol Metab 79:1818-1823
257. Yano K, Saji M, Hidaka A, Moriya N, Okuno A, Kohn LD, Cutler GB Jr (1995) A new constitutively activating point mutation in the luteinizing hormone/choriogonadotropin receptor gene in cases of male-limited precocious puberty. J Clin Endocrinol Metab 80:1162-1168
258. i1 by lysophosphatidic acid receptor without ligand in the baculovirus expression system. Biochem Biophys Res Commun 259:78-84
259. Zaki PA, Keith DE Jr, Thomas JB, Carroll FI, Evans CJ (2001) Agonist-, antagonist-, and inverse agonist-regulated trafficking of the δ-opioid receptor correlates with, but does not require, G protein activation. J Pharmacol Exp Ther 298:1015-1020
260. 2 receptor dimers in human and rat brain. FEBS Lett 441:383-386
261. 3 muscarinic receptor dimers. J Biol Chem 274: 19487-19497
262. 2+ receptor. FEBS Lett 448:180-184
263. 2+ current in mouse ventricular myocytes. Mol Pharmacol 56:485-493
264. 2+ cycling to augment contraction in mouse heart. J Physiol (Lond) 521:351-361
265. 2 double knockout mice. Mol Pharmacol 58:887-894
266. 2-adrenergic receptor. J Biol Chem 273:3401-3407